Banco Santander S.A. Invests $7.31 Million in Biogen Inc. (NASDAQ:BIIB)

Banco Santander S.A. bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 47,809 shares of the biotechnology company’s stock, valued at approximately $7,311,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Machina Capital S.A.S. raised its holdings in shares of Biogen by 9.0% during the fourth quarter. Machina Capital S.A.S. now owns 5,605 shares of the biotechnology company’s stock valued at $857,000 after purchasing an additional 461 shares during the period. Andra AP fonden boosted its holdings in Biogen by 26.2% in the fourth quarter. Andra AP fonden now owns 33,700 shares of the biotechnology company’s stock worth $5,153,000 after acquiring an additional 7,000 shares in the last quarter. Edgestream Partners L.P. grew its stake in Biogen by 79.5% in the fourth quarter. Edgestream Partners L.P. now owns 20,135 shares of the biotechnology company’s stock valued at $3,079,000 after acquiring an additional 8,917 shares during the period. E Fund Management Co. Ltd. increased its holdings in shares of Biogen by 26.9% during the fourth quarter. E Fund Management Co. Ltd. now owns 10,227 shares of the biotechnology company’s stock valued at $1,564,000 after acquiring an additional 2,166 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Biogen during the fourth quarter worth approximately $21,710,000. 87.93% of the stock is owned by institutional investors.

Biogen Trading Up 2.0 %

Shares of Biogen stock opened at $150.38 on Friday. The stock has a market capitalization of $22.01 billion, a P/E ratio of 13.44, a P/E/G ratio of 1.51 and a beta of 0.01. Biogen Inc. has a 52-week low of $128.51 and a 52-week high of $238.00. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. The stock’s 50-day simple moving average is $143.98 and its 200 day simple moving average is $166.46.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. As a group, research analysts anticipate that Biogen Inc. will post 15.83 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Biogen in a research report on Thursday, February 13th. William Blair reiterated an “outperform” rating on shares of Biogen in a report on Monday, January 13th. Mizuho lowered their target price on shares of Biogen from $251.00 to $207.00 and set an “outperform” rating on the stock in a report on Thursday, November 21st. Canaccord Genuity Group cut their price target on Biogen from $298.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Finally, Sanford C. Bernstein started coverage on Biogen in a report on Tuesday, February 11th. They set a “market perform” rating and a $160.00 price objective for the company. Seventeen research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $213.33.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.